Cost-effectiveness analysis reveals finotonlimab plus chemotherapy may lack economic viability for R/M HNSCC, suggesting price reductions could help.
Although finotonlimab combined with chemotherapy provides clinical benefits for patients with R/M HNSCC, it is not cost-effective at current pricing in China. Substantial price reductions, biomarker-guided patient selection, and inclusion in national reimbursement programs may improve its economic viability.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: